Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD3 epsilon Antibody (PC3/188A), Novus Biologicals™
Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP25338620UG
Description
CD3 epsilon Monoclonal specifically detects CD3 epsilon in Human, Rat, Porcine, Bovine, Chicken, Equine, Guinea Pig, Rabbit samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
CD3 epsilon | |
Monoclonal | |
0.2 mg/mL | |
Western Blot 1 - 2 ug/ml, Flow Cytometry 0.5 - 1 ug/million cells, Immunocytochemistry/Immunofluorescence 1 - 2 ug/ml, Immunohistochemistry-Paraffin 1 - 2 ug/ml, SDS-Page | |
CD3e antigen, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), CD3-epsilon, FLJ18683, T3E, T-cell antigen receptor complex, epsilon subunit of T3, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, TCRE | |
Mouse | |
20 kDa | |
20 μg | |
Adaptive Immunity, Apoptosis, Cytokine Research, Diabetes Research, Immunology, Innate Immunity, Mesenchymal Stem Cell Markers, Signal Transduction, Stem Cell Lines, Stem Cell Markers | |
916 | |
Store at 4C. | |
IgG1 |
Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), SDS-Page | |
PC3/188A | |
Unconjugated | |
10mM PBS with 0.05% BSA with 0.05% Sodium Azide | |
CD3E | |
A synthetic peptide corresponding to amino acids 156-168 of the cytoplasmic domain of human CD3-? chain | |
Protein A purified | |
RUO | |
Primary | |
Human, Rat, Porcine, Bovine, Chicken, Equine, Rabbit | |
Purified |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?
Provide Content Correction